{"issuance_frequency":"","notes_translated":{"fr":"Au moment de l’autorisation, aucune préoccupation majeure en matière d’innocuité n’a été révélée par les données disponibles transmises à Santé Canada. Nous surveillons étroitement l’innocuité et l’efficacité des vaccins autorisés contre la COVID‑19 après leur mise en marché (après leur autorisation). Dans le respect de notre engagement à garder les Canadiens informés, nous publions de l’information sur les effets secondaires suivant l’immunisation (ESSI).","en":"At the time of authorization, no major safety concerns have been reported in the available data submitted to Health Canada. We are carefully monitoring the post-market (after authorization) safety and effectiveness of authorized COVID-19 vaccines. As part of our commitment to keep Canadians informed, we are publishing information about adverse events following immunization (AEFI). "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"44887c84-8e32-4e78-9dda-ba08000d5ad7","metadata_created":"2021-07-29T12:11:47.178757","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-29T12:11:47.178764","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-29","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["COVID-19","pandémie","vaccin Moderna COVID-19","vaccins COVID-19 autorisés","besoins urgents de santé publique","autorisation de mise sur le marché","surveillance continue","sécurité post-commercialisation","efficacité","effets indésirables après vaccination","MAPI"],"en":["COVID-19","pandemic","Moderna COVID-19 vaccine","authorized COVID-19 vaccines","urgent public health needs","market authorization","continued monitoring","post-market safety","effectiveness","adverse events following immunization","AEFI"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Vaccin de Moderna contre la COVID-19 : Surveillance continue","en":"Moderna COVID-19 vaccine: Continued monitoring"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"44887c84-8e32-4e78-9dda-ba08000d5ad7","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4db02c17-d483-452d-a8d3-9e02ee9a1a7f","related_relationship":"","name_translated":{"fr":"Vaccin de Moderna contre la COVID-19 : Surveillance continue","en":"Moderna COVID-19 vaccine: Continued monitoring"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Moderna COVID-19 vaccine: Continued monitoring","language":["en"],"created":"2021-07-29T12:11:47.253931","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/moderna/monitoring.html","last_modified":null,"position":0,"revision_id":"acf42252-85a1-4f38-a366-cd8fce91cd31","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"44887c84-8e32-4e78-9dda-ba08000d5ad7","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6b4ba4f1-d307-4602-9443-ed696b4ae2b2","related_relationship":"","name_translated":{"fr":"Vaccin de Moderna contre la COVID-19 : Surveillance continue","en":"Moderna COVID-19 vaccine: Continued monitoring"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Moderna COVID-19 vaccine: Continued monitoring","language":["fr"],"created":"2021-07-29T12:11:47.253938","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/vaccins/moderna/surveillance.html","last_modified":null,"position":1,"revision_id":"acf42252-85a1-4f38-a366-cd8fce91cd31","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2021-03-22 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"44887c84-8e32-4e78-9dda-ba08000d5ad7","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"At the time of authorization, no major safety concerns have been reported in the available data submitted to Health Canada. We are carefully monitoring the post-market (after authorization) safety and effectiveness of authorized COVID-19 vaccines. As part of our commitment to keep Canadians informed, we are publishing information about adverse events following immunization (AEFI). ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Moderna COVID-19 vaccine: Continued monitoring","revision_id":"acf42252-85a1-4f38-a366-cd8fce91cd31"}